Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
PHASE1
This phase I trial studies the side effects and best dose of autologous CD8...
Status
Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
PHASE3
In this study, the efficacy and safety of two nilotinib doses, 300 mg twice...
Status
Completed
Location
University of California at Los Angeles Dept. of Hematology Clinic